Kintara Therapeutics Granted Fast Track Designation from FDA for REM-001 for Cutaneous Metastatic…
Kintara Therapeutics, Inc. announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Kintara's REM-001 Therapy for the treatment of…
Read More...
Read More...
